BRAF-based polypeptides for treatment of cancer
US11338012B2 · kind B2 · utility
3Cited by
0References
22Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | May 13, 2020 |
| Grant date | May 24, 2022 |
| Priority date | — |
| Expiry date | May 13, 2040 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2319/43
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
In one aspect, the invention provides a polypeptide derived from the dimer interface of BRAF, which is useful for treating various types of cancers. In certain embodiments, the polypeptide can be used to treat, prevent, and/or ameliorate a cancer such as but not limited to lung cancer.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.